|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002085,
umls-concept:C0002395,
umls-concept:C0003595,
umls-concept:C0006104,
umls-concept:C0178602,
umls-concept:C0311400,
umls-concept:C0439849,
umls-concept:C0445223,
umls-concept:C0547047,
umls-concept:C1552599,
umls-concept:C1704787
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-2-17
|
|
pubmed:abstractText |
Declines in brain glucose metabolism have been described early in Alzheimer's disease (AD), and there is evidence that a genetic predisposition to AD contributes to accelerate this process. The epsilon 4 (e4) allele of the apolipoprotein E (ApoE) gene has been implicated as a major risk factor in this process. The aim of this FDG-PET study was to assess the ApoE e4 dose related effect on regional cerebral glucose metabolism (METglc) in clinical AD patients, with statistical voxel based methods.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-10408560,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-10682216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-10811879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-10912591,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-11248079,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-11526211,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-11884488,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-11889238,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-12122177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-12163621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-12482085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-12595205,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-1869921,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-2011243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-2050758,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-6610841,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-7884953,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-8071705,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-8103819,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-8346443,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-8592548,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-8618881,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-8624095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-8648331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-8938259,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9074396,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9343467,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9633695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9633698,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9647302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9674794,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9823831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9876966,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14966149-9929679
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-3050
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
370-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:14966149-Aged,
pubmed-meshheading:14966149-Alzheimer Disease,
pubmed-meshheading:14966149-Apolipoprotein E4,
pubmed-meshheading:14966149-Apolipoproteins E,
pubmed-meshheading:14966149-Brain,
pubmed-meshheading:14966149-Case-Control Studies,
pubmed-meshheading:14966149-Female,
pubmed-meshheading:14966149-Fluorodeoxyglucose F18,
pubmed-meshheading:14966149-Gene Dosage,
pubmed-meshheading:14966149-Genetic Predisposition to Disease,
pubmed-meshheading:14966149-Glucose,
pubmed-meshheading:14966149-Humans,
pubmed-meshheading:14966149-Male,
pubmed-meshheading:14966149-Phenotype,
pubmed-meshheading:14966149-Radiopharmaceuticals,
pubmed-meshheading:14966149-Severity of Illness Index,
pubmed-meshheading:14966149-Tomography, Emission-Computed
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease.
|
|
pubmed:affiliation |
Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Italy.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
